FDA Approves Radicava for ALS Treatment

 

A successful leader with a strong entrepreneurial background, Shawn Tillitt established Jet Clean Janitorial, Inc., a commercial cleaning company in California, in 2007. He developed the firm from the ground up, growing the business by providing dedicated customer service and exceptional results. Committed to giving back to his community, Shawn Tillitt has made substantial contributions to nonprofits that support amyotrophic lateral sclerosis (ALS) research.

In May 2022, the FDA approved the use of edaravone for ALS treatment. Also known as Lou Gehrig's disease, ALS is a nervous system disorder that causes progressive paralysis of muscles in various parts of the body. Based on data put together by healthline.com, roughly 30,000 Americans are living with ALS. The neurological disorder has no cure, and treatments are essentially targeted at managing symptoms and increasing the life expectancy of patients.

Edaravone is an oral version of an existing ALS drug called Radicava. Radicava can only be administered intravenously, which is done on a weekly basis in hospitals or other healthcare settings. This understandably presents an additional burden for ALS patients, especially those who experience difficulty with the movement of their arms or legs. Since edaravone is administered orally, it can be taken at home, making it significantly easier for patients to adhere to treatment plans.